Rezultati pretraživanja
  1. prije 1 sat
  2. prije 3 sata

    obtained an exclusive world-wide license to develop and commercialize the investigational humanized onoclonal antibody XmAb7195 from Xencor . will make an upfront payment to of $5 million in cash and $5 million in equity

  3. prije 4 sata

    I'll have my bear burger medium rare with mushroom and swiss please. 3.40 % change recently

  4. prije 5 sati

    Aimmune up 10% premarket on increased Nestlé stake , ,

  5. prije 8 sati

    Trimmed more and

  6. prije 8 sati

    license for XmAb7195, a Phase 1 asset. Wondering why no Xolair combo trial? Will be interesting to see different effects between combo with Dupixant vs XmAb7195.

  7. prije 9 sati

    Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

  8. Odgovor korisniku/ci

    really running like a well oiled machine...

  9. prije 11 sati

    Couple of trades this morning: Sold out of , , , Trimmed: Added to:

  10. prije 12 sati

    After the (hardly expected) strategically reasonable out-licensing of XmAb7195, the probability that will also find a good solution for XmAb5871 is now increasing. This should boost the share price.

  11. prije 12 sati

    Despite the small upfront ($10 million) this is a very good deal for . 1. has a very strong partner in who has invested an additional $200 million in AIMT due to the in-licensing of XmAb7195.

    Prikaži ovu nit
  12. Big news for Aimmune just after announcing a pact with Xencor for XMAB7195

  13. Xencor Inc Receives Consensus Rating of “Buy” from Brokerages

  14. 4. velj
    Odgovor korisniku/ci

    It is fair to say in this context that tafasitamab was developed by .

  15. 3. velj

    Xencor Receives New Coverage from Analysts at Royal Bank of Canada

  16. 30. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.